• CBD Attenuates Orofacial Inflammatory Pain via Endocannabino

  2026-07-27

  This study demonstrates that cannabidiol (CBD) robustly reduces both sensory and affective components of orofacial inflammatory pain in mice, primarily by modulating endocannabinoid and serotonergic signaling. The findings highlight the translational potential of targeting endocannabinoid pathways, including CB1 and CB2 receptors, for comprehensive pain management strategies.

• Calpain Inhibitor II, ALLM: Precision Tools for Apoptosis As

  2026-07-27

  Calpain Inhibitor II, ALLM delivers high specificity for calpain and cathepsin targets, enabling robust apoptosis and protease inhibition workflows. This article translates recent mechanistic insights into actionable protocols for leukemia, lymphoma, and breast cancer models.

• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-07-26

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent designed for efficient amide bond formation in peptide synthesis, bioconjugation, and nucleotide coupling workflows. It is intended strictly for in vitro laboratory use, as no in vivo or clinical data are available.

• PD 0332991 (Palbociclib) HCl: Optimizing CDK4/6 Assays in Tu

  2026-07-25

  PD 0332991 (Palbociclib) HCl unlocks precise cell cycle arrest and robust tumor growth suppression in translational oncology. Learn how to deploy this selective CDK4/6 inhibitor for advanced experimental workflows, troubleshoot common pitfalls, and leverage breakthrough mechanistic insights for high-impact research outcomes.

• ICG001: Applied Workflows for Wnt/β-Catenin Pathway Inhibiti

  2026-07-24

  ICG001 is a selective Wnt/β-catenin pathway inhibitor enabling high-resolution dissection of CBP-mediated transcription in cancer and fibrosis models. This article bridges the latest mechanistic insights with actionable lab protocols, troubleshooting strategies, and translational considerations for maximizing ICG001’s impact in bench-to-bedside research.

• ML385: Expanding NRF2 Inhibition Beyond Cancer to Neuroprote

  2026-07-24

  Explore how ML385, a potent NRF2 inhibitor, is redefining research on oxidative stress, cancer resistance, and neurodegeneration. This article uniquely bridges recent evidence on ferroptosis and cognitive decline for advanced assay design.

• Obeticholic Acid in Liver Fibrosis: Advanced Applications &

  2026-07-23

  Obeticholic Acid (6alpha-ethyl-chenodeoxycholic acid) redefines liver fibrosis and hepatic inflammation research via potent FXR agonism, offering unique mechanistic and workflow advantages for MASLD, portal hypertension, and gene regulation studies. Explore protocol enhancements, comparative insights, and troubleshooting strategies for maximized reproducibility.

• 6-Thioguanine Suppresses EV71 Replication via BIRC3-Mediated

  2026-07-23

  This study demonstrates that 6-thioguanine (6-TG) inhibits Enterovirus 71 (EV71) replication in vitro by targeting BIRC3-mediated autophagy. The mechanistic insight into the antiviral action of 6-TG offers a promising direction for the development of targeted therapies against EV71, a major cause of severe hand, foot, and mouth disease in children.

• β-Amanitin: Mechanistic Insight and Strategy for Translation

  2026-07-22

  This thought-leadership article explores the role of β-Amanitin as a molecular probe in RNA polymerase II transcription studies, its pivotal applications in translational research, and the evolving landscape of toxin detection. By integrating mechanistic insights, protocol guidance, and competitive benchmarking, this piece empowers researchers to leverage β-Amanitin for high-impact gene regulation and toxicology studies—while advancing a vision for next-generation biosensing informed by computational antibody design.

• Methoxy-X04: Next-Generation Amyloid Beta Imaging in Alzheim

  2026-07-22

  Explore the advanced capabilities of Methoxy-X04, a fluorescent amyloid beta probe, in unraveling Alzheimer’s pathology. This article uniquely analyzes practical assay refinement and translational insights for researchers leveraging Methoxy-X04 in cutting-edge neurodegenerative disease research.

• Exo1: Precision Membrane Trafficking Inhibition for Exocytos

  2026-07-21

  Exo1, a methyl 2-(4-fluorobenzamido)benzoate-based inhibitor, enables rapid and selective disruption of ER-to-Golgi membrane trafficking, offering researchers a tool distinct from legacy compounds like Brefeldin A. Its unique action on ARF1 and the Golgi apparatus translates to advanced exocytosis and vesicle trafficking assays, with tangible advantages for experimental clarity and troubleshooting.

• Dabigatran Safety: Literature Review and Adverse Event Manag

  2026-07-21

  This review critically examines the safety profile of dabigatran (Pradaxa) in stroke prevention for atrial fibrillation, with a focus on adverse events and practical recommendations for their management. The paper synthesizes clinical and case report evidence, offering guidance on balancing efficacy with bleeding and other risks in anticoagulation therapy.

• Smoothened Agonist (SAG): Precision Hedgehog Pathway Activat

  2026-07-20

  Smoothened Agonist (SAG) is a selective Hedgehog pathway activator with proven efficacy in mitochondrial protection, myelin regeneration, and developmental biology research. SAG’s specificity and solubility profile enable robust experimental control across cell and animal models.

• LINC01278 Suppresses Uveal Melanoma via mTOR Pathway Inhibit

  2026-07-20

  This study identifies LINC01278 as a tumor-suppressive lncRNA in uveal melanoma (UM) that induces autophagy by suppressing mTOR signaling. The findings highlight a novel mechanism for UM progression control and provide a foundation for targeting the LINC01278-mTOR axis in future therapeutic strategies.

• Poria cocos Polysaccharides Mitigate ALD via NRF2-Regulated

  2026-07-19

  This study demonstrates that Poria cocos polysaccharides (PCP) improve alcoholic liver disease (ALD) by modulating ferroptosis through NRF2 signaling regulation. Using both in vivo and in vitro models, the authors establish a mechanistic link between NRF2 pathway modulation, oxidative stress, and cell death, highlighting PCP’s therapeutic potential in ALD intervention.

14884 records 1/993 page Next 12345 下5页 Last page